Search Results

You are looking at 1 - 2 of 2 items for

  • Author or Editor: Douglas E. Hutchens x
  • Refine by Access: All Content x
Clear All Modify Search

Abstract

Objective—To evaluate the safety of moxidectin administration at doses of 30, 60, and 90 µg/kg of body weight (10, 20, and 30 times the manufacturer's recommended dose) in avermectin-sensitive Collies.

Animals—24 Collies.

Procedure—Collies with mild to severe reactions to ivermectin challenge (120 mg/kg; 20 times the recommended dose for heartworm prevention) were used. Six replicates of 4 dogs each were formed on the basis of body weight and severity of reaction to ivermectin test dose. Within replicates, each dog was randomly allocated to treatment with oral administration of 30, 60, or 90 µg of moxidectin/kg or was given a comparable volume of placebo tablet formulation. Dogs were observed hourly for the first 8 hours and twice daily thereafter for 1 month for signs of toxicosis.

Results—Signs of toxicosis were not observed in any control group dog throughout the treatment observation period. Likewise, signs of toxicosis were not observed in any dog receiving moxidectin at 30, 60, or 90 µg/kg.

Conclusions and Clinical Relevance—The moxidectin formulation used in the study reported here appears to have a wider margin of safety than ivermectin or milbemycin in avermectin-sensitive Collies. (Am J Vet Res 2000;61:482–483)

Full access
in American Journal of Veterinary Research

Abstract

Objective—To evaluate the safety of dermal application of 10.0% imidacloprid-0.08% ivermectin in ivermectin- sensitive Collies at dose rates of 3 to 5 times the proposed maximum therapeutic dose.

Animals—15 Collies (5 males and 10 females) that were confirmed as ivermectin-sensitive dogs.

Procedure—Dogs were assigned to 3 treatment groups (control, 3×, or 5× group) in a randomized block design on the basis of the maximal ivermectinsensitivity score obtained during preliminary screening. Dogs in groups 3× and 5× were treated at 3 and 5 times the maximum label dose, respectively. Control dogs received an application of an equal volume of a nonmedicated solution. Observation and scoring on all days were conducted to specifically include neurologic signs typical of ivermectin toxicosis, including lethargy, ataxia, abnormal mydriasis, and abnormal salivation.

Results—None of the dogs had clinical abnormalities during the study period.

Conclusions and Clinical Relevance—Analysis of results of this study indicates that dermal application of 10.0% imidacloprid-0.08% ivermectin is safe for use in ivermectin-sensitive Collies at dose rates of 3 or 5 times the proposed maximum therapeutic dose. ( Am J Vet Res 2004;65:277–278)

Full access
in American Journal of Veterinary Research